Back to top

Research Daily

Tuesday, November 6, 2018

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Amgen (AMGN), Intercontinental Exchange (ICE) and TOTAL S.A. (TOT). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Amgen’s shares have gained +9.2% year to date versus the Zacks Biomedical and Genetics industry's decline of -16.6%. Amgen beat expectations for both earnings and sales in the third quarter of 2018 and also raised full-year expectations for both.

The Zacks analyst emphasizes that Amgen’s newer drugs – Prolia, Xgeva, Blincyto, Repatha, Kyprolis – are performing well. Amgen is also progressing with its pipeline and the recent approval of migraine candidate, Aimovig was a huge boost. Amgen has a strong biosimilars pipeline, which could be an important long-term growth driver.

However, Amgen faces challenges related to more mature products such as launch of competing biosimilar versions of Neulasta and Epogen, further sales erosion of Neupogen and Aranesp and increasing competitive pressures on Enbrel. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions and the recent price cut will hurt sales, going forward.

(You can read the full research report on Amgen here >>>).

Shares of Buy-ranked Intercontinental Exchange have underperformed the Zacks Securities and Exchanges industry year to date, gaining +10.9% versus +18.8%. Intercontinental Exchange’s third-quarter 2018 earnings beat expectations and also improved year over year on record revenues.

The Zacks analyst thinks Intercontinental Exchange’s successful integration of acquisitions, achievement of cost synergies and reduced debt level poise the company for long-term growth. Moreover, a continued strength in its energy franchise, improving recurring market data revenues and ongoing initiatives should keep growth on track.

However, rising expenses, foreign currency fluctuations and stricter regulations raise concerns. The company estimates 2018 operating expenses in the range of $2.04-$2.05 billion and adjusted operating expense in the band of $2-$2.04 billion. Interest expenses are anticipated at $73 million for fourth-quarter 2018.

(You can read the full research report on Intercontinental Exchange here >>>).

TOTAL S.A.’s shares have gained +5.8% year to date, outperforming the Zacks Integrated International Oil industry which has declined -1.5% over the same period. The company’s earnings and revenues in the last reported quarter surpassed expectations, courtesy of improvement in commodity prices, as well as strong contribution from new upstream projects.

In addition, strategic acquisitions strengthened its portfolio and helped expand its operations. The Zacks analyst thinks the company is utilizing its strong cash-flow generating capacity to strengthen balance sheet and repurchase outstanding shares, which is positively impacting earnings.

However, operations in some politically-troubled regions and increasing competition could impact the company’s profitability. Due to its global presence, it is also exposed to risks associated with doing business abroad.

(You can read the full research report on TOTAL S.A. here >>>).

Other noteworthy reports we are featuring today include Royal Dutch Shell (RDS.A), Sysco (SYY) and Williams (WMB).

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Featured Reports

New Upgrades

New Downgrades